Sclerostin antibody (N-Term)
Quick Overview for Sclerostin antibody (N-Term) (ABIN2840682)
Target
See all Sclerostin (SOST) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 12-42, N-Term
-
Predicted Reactivity
- B
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This SOST antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 12-42 amino acids from the N-terminal region of human SOST.
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB: 1:1000. WB: 1:2000. WB: 1:1000. WB: 1:2000. IHC-P-Leica: 1:500
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid freeze-thaw cycles.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots.
-
Expiry Date
- 6 months
-
-
-
: "Co-expression of DKK-1 and Sclerostin in Subchondral Bone of the Proximal Femoral Heads from Osteoarthritic Hips." in: Calcified tissue international, Vol. 100, Issue 6, pp. 609-618, (2018) (PubMed).
: "Single-pulsed electromagnetic field therapy increases osteogenic differentiation through Wnt signaling pathway and sclerostin downregulation." in: Bioelectromagnetics, Vol. 36, Issue 7, pp. 494-505, (2015) (PubMed).
-
: "Co-expression of DKK-1 and Sclerostin in Subchondral Bone of the Proximal Femoral Heads from Osteoarthritic Hips." in: Calcified tissue international, Vol. 100, Issue 6, pp. 609-618, (2018) (PubMed).
-
- Sclerostin (SOST)
-
Alternative Name
- SOST
-
Background
- Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
-
Molecular Weight
- 24031
-
Gene ID
- 50964
-
NCBI Accession
- NP_079513
-
UniProt
- Q9BQB4
Target
-